ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer

Thursday, September 19, 2013

Submitted by

Source

Source Name: Journal of the National Cancer Institute

Source URL: http://jnci.oxfordjournals.org/content/105/18/1385.abstract.html?etoc

Author(s)

Daniel Ajona, María J. Pajares, Leticia Corrales, Jose L. Perez-Gracia, Jackeline Agorreta, Maria D. Lozano, Wenceslao Torre, Pierre P. Massion, Juan P. de-Torres, Eloisa Jantus-Lewintre, Carlos Camps, Javier J. Zulueta, Luis M. Montuenga and Ruben Pio

In this promising investigation, investigators found that C4d, a degradation product of complement activation, assessed in bronchoalveolar lavage and plasma, predicts the presence of lung cancer compared with non-cancer patients. They found a shorter survival in patients with high levels in the plasma. Plasma C4d levels were reduced after surgical resections, which means C4d may be useful as a marker of recurrence after resection.